Feb. 21, 2012
The drug discovery company Hutchison MediPharma announced on February 22, 2012 that it has begun a first-in-human Phase I clinical trial of a cancer drug, volitinib (HMPL-504), in Australia. The Phase I clinical trial will serve for the purpose of evaluating the safety, tolerance and initial efficacy to treat various cancers including lung cancer and gastric cancer.
Volitinib, the fourth cancer drug that the company has brought to clinical trials, is a novel inhibitor of the c-Met receptor tyrosine kinase. In December 2011, Hutchison MediPharma entered a co-licensing agreement for the molecule with AstraZeneca in a $140 million deal. AstraZeneca assumed responsibility for developing Volitinib outside of China.